EP4367140A4 - ANTI-TNFR2 ANTIBODY AND ITS USES - Google Patents

ANTI-TNFR2 ANTIBODY AND ITS USES

Info

Publication number
EP4367140A4
EP4367140A4 EP22837100.1A EP22837100A EP4367140A4 EP 4367140 A4 EP4367140 A4 EP 4367140A4 EP 22837100 A EP22837100 A EP 22837100A EP 4367140 A4 EP4367140 A4 EP 4367140A4
Authority
EP
European Patent Office
Prior art keywords
tnfr2 antibody
tnfr2
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP22837100.1A
Other languages
German (de)
French (fr)
Other versions
EP4367140A1 (en
Inventor
Nicola Arturo Aldo BELTRAMINELLI
Jennifer Watkins
Francisco Adrian
Qian Zhang
Andreas Raue
Pascaline Mary
Liang SCHWEIZER
Shuo WEI
Matthieu DELINCE
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hifibio Inc
Original Assignee
Hifibio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hifibio Inc filed Critical Hifibio Inc
Publication of EP4367140A1 publication Critical patent/EP4367140A1/en
Publication of EP4367140A4 publication Critical patent/EP4367140A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP22837100.1A 2021-07-07 2022-07-06 ANTI-TNFR2 ANTIBODY AND ITS USES Pending EP4367140A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163219175P 2021-07-07 2021-07-07
PCT/IB2022/000409 WO2023281313A1 (en) 2021-07-07 2022-07-06 Anti-tnfr2 antibody and uses thereof

Publications (2)

Publication Number Publication Date
EP4367140A1 EP4367140A1 (en) 2024-05-15
EP4367140A4 true EP4367140A4 (en) 2025-06-18

Family

ID=84800439

Family Applications (1)

Application Number Title Priority Date Filing Date
EP22837100.1A Pending EP4367140A4 (en) 2021-07-07 2022-07-06 ANTI-TNFR2 ANTIBODY AND ITS USES

Country Status (9)

Country Link
EP (1) EP4367140A4 (en)
JP (1) JP2024527576A (en)
KR (1) KR20240032985A (en)
CN (1) CN117980336A (en)
AR (1) AR126387A1 (en)
AU (1) AU2022308421A1 (en)
CA (1) CA3224693A1 (en)
TW (1) TW202309096A (en)
WO (1) WO2023281313A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3256751A1 (en) * 2022-05-26 2023-11-30 Pfizer Inc. Anti-tnfr2 antibodies and methods of use thereof
WO2024233258A1 (en) * 2023-05-05 2024-11-14 Cureimmune Therapeutics Inc. Anti-tnfr2 antibodies and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190135929A1 (en) * 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3707163A4 (en) * 2017-11-09 2021-08-18 The General Hospital Corporation ANTAGONISTIC POLYPEPTIDS OF THE ANTI-TUMOR NECROSIC FACTOR RECEPTOR SUPER FAMILY
CA3131953A1 (en) * 2019-03-01 2020-09-10 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof
WO2021023098A1 (en) * 2019-08-02 2021-02-11 江苏先声药业有限公司 Anti-tnfr2 antibody and use thereof
CA3154643A1 (en) * 2019-09-17 2021-03-25 Apexigen, Inc. Anti-tnfr2 antibodies and methods of use
CN112480259B (en) * 2021-02-05 2021-05-04 百奥赛图(北京)医药科技股份有限公司 anti-TNFR 2 antibodies and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020061210A1 (en) * 2018-09-18 2020-03-26 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
See also references of WO2023281313A1 *
WEI SHUO ET AL: "DiscoveryandcharacterizationofnovelTNFR2antibodiestomodulateTcellactivities inimmunosuppressiveenvironment", AACR, vol. 80, 3 July 2020 (2020-07-03), pages 2282 - 2282, XP055913355, Retrieved from the Internet <URL:http://hifibio.com/wp-content/uploads/2020/07/Poster-2282-AACR-2020-conference-poster_TNFR2.pdf> [retrieved on 20250508], DOI: https://doi.org/10.1158/1538-7445.AM2020-2282 *

Also Published As

Publication number Publication date
AU2022308421A1 (en) 2024-01-25
CA3224693A1 (en) 2023-01-12
AR126387A1 (en) 2023-10-11
WO2023281313A1 (en) 2023-01-12
TW202309096A (en) 2023-03-01
EP4367140A1 (en) 2024-05-15
JP2024527576A (en) 2024-07-25
CN117980336A (en) 2024-05-03
KR20240032985A (en) 2024-03-12

Similar Documents

Publication Publication Date Title
EP3838289A4 (en) ANTI-TIGIT ANTIBODIES AND ITS USES
EP3958910A4 (en) ANTI-CD45-DRUG ANTIBODY CONJUGATES AND THEIR USES
EP4388009A4 (en) ANTI-CCR8 ANTIBODIES AND THEIR USES
EP3918323A4 (en) ANTI-GAL3 ANTIBODIES AND THEIR USES
EP3891183A4 (en) ANTI-CLAUDINE ANTIBODIES AND THEIR USES
EP4269435A4 (en) ANTI-B7-H3 ANTIBODY AND ITS USES
EP3762030A4 (en) ANTI-CD73 ANTIBODIES AND ASSOCIATED USES
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP4100439A4 (en) NEW ANTI-LILRB2 ANTIBODIES AND THEIR USES
EP4132974A4 (en) ANTI-CD98 ANTIBODIES AND THEIR USES
EP3735427A4 (en) ANTI-MCT1 ANTIBODIES AND ASSOCIATED USES
EP4261223A4 (en) ANTI-SIRP? ANTIBODY AND ITS APPLICATION
EP4281107A4 (en) ANTI-KIT ANTIBODIES AND THEIR USES
EP4136117A4 (en) ANTI-OX40 ANTIBODIES AND ITS USES
EP3790586A4 (en) ANTI-DLL3 ANTIBODIES AND THEIR USES
EP3962954A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
EP3850012A4 (en) ANTI-TNFRSF9 ANTIBODIES AND THEIR USES
MA52190A (en) ANTI-TREM-1 ANTIBODIES AND ASSOCIATED USES
EP3755714A4 (en) ANTI-ANGIOPOIETIN-2 ANTIBODIES AND THEIR USES
EP4010368A4 (en) ANTI-NAMPT ANTIBODIES AND THEIR USES
EP4081548A4 (en) ANTI-SIRP MONOCLONAL ANTIBODIES? AND THEIR USES
EP3768317A4 (en) ANTI-IL-27 ANTIBODIES AND THEIR USES
EP3947462A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
MA55134A (en) ANTI-STAPHYLOCOCCUS ANTIBODIES AND THEIR USES
EP4367140A4 (en) ANTI-TNFR2 ANTIBODY AND ITS USES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20240129

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: HIFIBIO, INC.

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20250520

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 39/39 20060101ALI20250514BHEP

Ipc: A61P 35/00 20060101ALI20250514BHEP

Ipc: C12N 15/13 20060101ALI20250514BHEP

Ipc: A61K 39/00 20060101ALI20250514BHEP

Ipc: C07K 16/28 20060101AFI20250514BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN